Onyx Pharmaceuticals,(Nasdaq:ONXX) recently announced that it will webcast a teleconference with management to provide a general business update on Monday, October 12, 2009, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time).
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
Interested parties may access a live webcast of the presentation on the company's website at: or by dialing 847-413-3362 and using the passcode 25577870#. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 25577870# approximately one hour after the teleconference concludes. The replay will be available through November 12, 2009. Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar®, a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Onyx Pharmaceuticals is a biopharmaceutical company committed to developing therapeutics that improves the lives of individuals with cancer. Our lead product is Nexavar® (sorafenib) tablets, an oral, targeted therapy approved in more than 80 countries worldwide for the treatment of patients with liver cancer and in more than 90 countries for the treatment of patients with advanced kidney cancer. We also have a development of anticancer therapies at various stages of clinical testing.Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has begun enrolling patients in a Phase 1 study of ONX 0801, a novel alpha-folate receptor-mediated thymidylate synthase (TS) inhibitor, as a potential treatment for advanced solid tumors. This open-label, dose-finding study will evaluate the safety and pharmacokinetics of ONX 0801 in patients with advanced solid tumors."We are pleased to advance this product candidate so quickly into the clinic, following our acquisition of the compound late last year. ONX 0801 has a high selectivity for cancer cells that we believe will distinguish it from other agents in this proven class of drugs,” said Tony Coles, M.D., president and chief executive officer of Onyx. “We expect this forward momentum in building our portfolio to continue, as we strategically maximize opportunities that will drive long-term sustainable growth.”
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
